🩺

Gastroenterology

58 drugs in pipeline from 10 companies

Drugs in Pipeline

Companies

Upcoming Catalysts

Phase 3 Trials

Upcoming Catalysts

Tomorrow

LSTAPhase 2$24M

certepetide Phase 2 Results Expected

certepetide• Cholangiocarcinoma67

Apr 18Estimated

CT.gov

00%

ANROPhase 2$590M

DR30206 Phase 2 Results Expected

DR30206• Gastrointestinal Cancer186

Apr 30Estimated

CT.gov

00%

AZNCFPhase 2$290.6B

AZD7798 Phase 2 Results Expected

AZD7798• Moderate to Severe Crohn's Disease120

May 1Estimated

CT.gov

00%

AZNPhase 2$317.6B

AZD7798 Phase 2 Results Expected

AZD7798• Crohn's Disease30

May 4Estimated

CT.gov

00%

ABBVPhase 3$300.2B

✓Positive

Risankizumab SC Phase 3 Results Expected

Risankizumab SC• Crohn's Disease1,336

May 15Estimated

CT.gov

View all catalysts

Pipeline by Phase

Phase 3

Active Companies

CELG-RI

BRISTOL MYERS SQUIBB CO

Novartis AG

Amgen Inc.

Gilead Sciences, Inc.

AstraZeneca PLC

ASTRAZENECA PLC

TAKEDA PHARMACEUTICAL CO LTD

2 drugs

TAK

TAKEDA PHARMACEUTICAL CO LTD

1 drugs

LLY

Eli Lilly and Company

2 drugs

ABT

ABBOTT LABORATORIES

4 drugs

Related Conditions

gastrointestinalgiliverhepaticcirrhosiscrohnulcerative colitisibsgerdpancreatitisceliacconstipationdiarrhea